An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer

Table 1

Summary of androgen deprivation indications.

ADT likely unwarranted	ADT still warranted
Localized disease	Advanced disease
(i) Preprostatectomy/postprostatectomy [30]	(i) PSA > 50, PSADT < 12 months [38]
(ii) Prior to EBXRT/Brachytherapy [33–36]	(ii) Prior to EBXRT [43–47]
(iii) No primary treatment [37]	(iii) Local obstructive symptoms and or metastatic disease [50]
(iv) Biochemical recurrence after therapy with PSADT > 12 months [53]	(iv) Lymph node involvement at prostatectomy [49]
	(v) Biochemical recurrence after therapy with high risk of death from prostate cancer [55–57],

Abbreviations. ADT: androgen deprivation therapy; EBXRT: external beam radiation; PSA: prostate-specific antigen; PSADT: prostate-specific antigen doubling time.